Anthony Griffin - Dechra Pharmaceuticals Managing Director
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
Managing Director
Mr. Anthony Gerard Griffin is a Managing Director Dechra Veterinary Products Europe, Executive Director of Dechra Pharmaceuticals PLC. Tony has over 30 years experience in the animal health business and has substantial international experience as a result of living and working outside the UK since 1993. He gained broad experience of running an international animal health business with teams in different European countries as Chief Executive Officer of the AUV Group. Tony is the Board nominated Director responsible for health, safety and environmental matters. Tony was appointed Managing Director of DVP EU in May 2012 following the acquisition of Eurovet Animal Health BV from AUV Holding B.V. He joined the AUV Group in 1993 as Director of Exports, having previously worked at Norbrook Laboratories and Moy Park. Tony was promoted to Managing Director of Eurovet in 1996, becoming the Chief Executive Officer of the AUV Group in 2006. since 2012.
| Age | 60 |
| Tenure | 12 years |
| Phone | 44 1606 814730 |
| Web | https://www.dechra.com |
Dechra Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0478 % which means that it generated a profit of $0.0478 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0896 %, meaning that it generated $0.0896 on every $100 dollars invested by stockholders. Dechra Pharmaceuticals' management efficiency ratios could be used to measure how well Dechra Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Dechra Pharmaceuticals PLC has accumulated 313.7 M in total debt with debt to equity ratio (D/E) of 0.5, which is about average as compared to similar companies. Dechra Pharmaceuticals has a current ratio of 2.85, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Dechra Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Dechra Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dechra Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dechra to invest in growth at high rates of return. When we think about Dechra Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom. Dechra Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 1699 people. Dechra Pharmaceuticals PLC [DPHAY] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Management Performance
| Return On Equity | 0.0896 | |||
| Return On Asset | 0.0478 |
Dechra Pharmaceuticals Leadership Team
Elected by the shareholders, the Dechra Pharmaceuticals' board of directors comprises two types of representatives: Dechra Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dechra. The board's role is to monitor Dechra Pharmaceuticals' management team and ensure that shareholders' interests are well served. Dechra Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dechra Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Griffin, Managing Director - Dechra Veterinary Products Europe, Executive Director | ||
| Patrick Meeus, Group Officer | ||
| Katy Clough, Group HR Director | ||
| FCCA MAAT, CFO Director | ||
| Ian Page, CEO, Executive Director | ||
| Melanie Hall, Company Sec | ||
| Mike Eldred, President North America |
Dechra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Dechra Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0896 | |||
| Return On Asset | 0.0478 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 4.04 B | |||
| Shares Outstanding | 56.92 M | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.99 X | |||
| Price To Sales | 5.65 X | |||
| Revenue | 681.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |